If Your Operation Touched An EUA, Start Looking For What It Left Behind
U.S. Department of Health and Human Services (HHS) has announced the termination of the Emergency Use Authorization declarations for drugs and biological products, and separately for medical devices. This does not
affect every life sciences company.
But for organizations that manufactured, distributed, supplied, tested, labeled, supported, or made commitments connected to an EUA-authorized product or process, the operational review should start now.
The declarations do not end overnight. The drug and biologics EUA declaration terminates 12 months after the determination, while the medical device EUA declarations terminate 180 days after the determination.
That timing matters because the risk is not only the termination date. The risk is what may still be sitting inside the business after the EUA environment changes: a labeling claim, an IFU reference, a supplier assumption, a distribution practice, an inventory decision, a customer commitment, or a change control that was never clearly closed, replaced, or converted into a permanent control.
Those details can become compliance problems later if no one owns the assessment now.
For affected organizations, a practical starting point is to ask:
Do labels, IFUs, packaging, website language, sales materials, and customer communications still match the current regulatory status and transition requirements?
Were emergency-era change controls formally closed, converted into permanent controls, or left without clear disposition?
Are suppliers, testing labs, CMOs, distributors, and other external partners still operating under assumptions that may no longer apply?
What product is in inventory, what can still be distributed, what may require relabeling, and what customer communication may be needed?
Are complaint handling, adverse event reporting, post-market surveillance, and quality system obligations still current?
Most importantly, document the assessment. The question is not only, “Did we look at it?” The better question is, “Can we show what was evaluated, what decisions were made, who approved them, and why those decisions were appropriate?”
The end of an EUA is not just a regulatory date. For affected organizations, it is a test of whether the company can translate regulatory change into clear operational action across different timelines.
For organizations affected by EUA transition, MEDVACON LIFE SCIENCES, LLC brings structure to the work that now needs to happen: reviewing what changed, identifying what still depends on the prior authorization environment, determining what needs to be closed or updated, assigning ownership, documenting decisions, and closing gaps before questions come from FDA, customers, distributors, or internal leadership.